THE METAPLEX PLATFORM
Metaplex is a technology platform that uses coordination chemistry to create new nanomedicines. This platform can be applied to small molecules as well as poorly soluble compounds that cannot be remotely loaded into nanoparticles using conventional methods. The resulting products are safe and suitable for pharmaceutical development including oral, parenteral, and inhalation delivery.
Cuprous' proprietary technologies have potential to
• increase the solubility of sparingly or poorly soluble small molecules
• reduce Cmax-related toxicity
• improve therapeutic activity
• scale up for manufacturing
Cuprous' goal is to bring its technologies to the clinic through development of strategic partnerships. Cuprous is well-positioned to provide CMC support for the development of liposomal drug products.
Cuprous works with partners to develop small molecule nanomedicines with particular focus in the following disease indications. Contact us to discuss potential collaborative opportunities!
CANCER & IMMUNO-ONCOLOGY
Cuprous' Metaplex technology can be used to improve therapeutic activity of anticancer agents and create novel immunotherapeutics. Cuprous is also developing technologies to enhance immunotherapeutic effects of small molecules and to boost therapeutic activity of other modalities of immunotherapy such as checkpoint inhibitors, oncolytic viruses, and peptide vaccines.
Cuprous' Metaplex technology can be used to deliver antimicrobial small molecules and metal-activated antimicrobial agents. Cuprous is well-positioned to conduct pre-clinical studies in this area.